Developer docs
API playgroundTry for free, no card

Search company profiles

PsychoGenics

Full company profile

uuid0003k9f

Namestring
PsychoGenics
Legal namestring
PsychoGenics Inc.
Company typeenum
Private
Founded yearint
2002
Descriptiontext

PsychoGenics is a private, CNS-focused preclinical contract research organization (CRO) headquartered in Paramus, New Jersey, founded in 1999. The company combines a comprehensive suite of standard preclinical services (behavioral testing, electrophysiology, EEG, biomarker analysis, histology, microdialysis, PK/PD, receptor occupancy) with four proprietary AI-enabled phenotypic drug discovery platforms branded as the Cube technologies: SmartCube (high-throughput automated behavioral phenotyping with ML classifiers trained on thousands of reference compounds), NeuroCube (computer vision-based gait analysis for motor and pain disorders), PhenoCube (continuous day-and-night observation of social, circadian, motor, and cognitive behaviors), and eCube (pharmaco-EEG with proprietary qEEG reference database). The SmartCube platform notably contributed to the discovery of ulotaront, now in Phase III clinical trials with Sumitomo Pharma for schizophrenia, depression, and anxiety. The company maintains AAALAC International accreditation (since 2007), PHS OLAW Assurance (since 2005), and DEA Schedule 1 handling capability, and has established more than 400 client relationships with a >70% client return rate.

PsychoGenics generates revenue through three primary streams: (1) fee-for-service preclinical CRO contracts for biopharmaceutical companies, academic institutions, and disease research foundations; (2) shared-risk drug discovery partnerships with major pharma (Sunovion, Roche, Karuna Therapeutics, Sumitomo Pharma), where the company applies its Cube platforms to discover novel compounds potentially yielding licensing/milestone revenue; and (3) non-dilutive government research grants and contracts, including a recent $80M NIH HEAL Initiative IDIQ contract over five years for pain therapeutic screening and SBIR grants from NIMH for rare disease and mental health programs. The company serves named customers including Sumitomo Pharma, Sunovion, Roche, Karuna Therapeutics, NIH/NIMH, the SMA Foundation, CHDI Foundation, TSC Alliance, CMTA, Michael J. Fox Foundation, Christopher & Dana Reeve Foundation, and Grace Science. Recent product line extensions include cell and gene therapy preclinical testing, psychedelics research, and microbiome studies, expanding beyond traditional CNS behavioral services.

The go-to-market motion is sales-led and B2B, relying on direct enterprise field sales, conference engagement (Society for Neuroscience, NNT, AHS), the Scientist.com marketplace (where the company achieved top supplier status), and long-term disease foundation partnerships that serve as both collaborators and referral channels. Pricing is quote-based and project-specific rather than publicly disclosed. The company has 101-250 employees, over 20% holding Ph.D.s, and is led by President and CEO Emer Leahy, Ph.D., MBA, with a Ph.D.-credentialed executive team across innovation, operations, research, and commercial functions.

Short descriptiontext

PsychoGenics is a private CNS-focused preclinical CRO that combines AI-enabled phenotypic drug discovery platforms (SmartCube, NeuroCube, PhenoCube, eCube) with full-service preclinical testing for biopharma, disease foundations, government agencies, and academic institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParamus, United States
HQ citystring
Paramus
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CNS research, contract research organization, phenotypic drug discovery, behavioral pharmacology services, AI-enabled in vivo platforms
Industry4 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Preclinical CRO Contract Services
TypeProfessional Services
Description

PsychoGenics generates revenue primarily through fee-for-service contracts for preclinical CNS drug discovery research. Services include behavioral testing, electrophysiology, EEG studies, biomarker analysis, histology, microdialysis, PK/PD, and receptor occupancy studies. Revenue is project-based and recurring as clients return for additional studies (>70% client return rate).

psychogenics.com
2Shared-Risk Drug Discovery Partnerships
TypeLicensing Royalties
Description

PsychoGenics enters shared-risk partnerships with biopharma companies (Sunovion, Roche, Karuna) where the company applies its Cube platforms to discover novel compounds. Partnerships may include licensing of discovered compounds or milestone payments, representing an additional revenue stream alongside service fees.

psychogenics.com
3Government Research Grants
TypeSubscription Recurring
Description

PsychoGenics receives SBIR grants from NIH (NIMH) and government contracts (NIH HEAL Initiative) to fund specific drug discovery programs. These grants (e.g., $3M SBIR, $80M NIH IDIQ contract) provide non-dilutive funding for research activities.

psychogenics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom preclinical study contracts — pricing negotiated per project based on scope of work, animal model, and assay requirements.
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. As a CRO providing bespoke preclinical services, pricing is determined by study design complexity, number of animals, specific assays, and project duration.

psychogenics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PsychoGenics is a preclinical contract research organization (CRO) that provides CNS-focused drug discovery and research services to biopharmaceutical companies, disease foundations, and government agencies. The company combines proprietary AI-enabled phenotypic platforms (SmartCube, NeuroCube, PhenoCube, eCube) with a full suite of preclinical services including behavioral testing, electrophysiology, EEG, biomarker analysis, histology, microdialysis, PK/PD, and receptor occupancy studies. It also engages in shared-risk drug discovery partnerships with major pharma, leading to clinical-stage compounds such as ulotaront.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • A potential clinical candidate can be identified after screening fewer than 300 compounds in lead optimization — a fraction of compounds typically tested in target-based approaches — substantially reducing discovery timelines and costs.
+3 more records
Product overview1 text field

PsychoGenics is a preclinical Contract Research Organization (CRO) specializing in CNS and orphan disorder drug discovery. The company offers a platform-plus-services architecture centered on four proprietary AI-enabled Cube platforms: SmartCube (high-throughput behavioral phenotyping), NeuroCube (gait analysis for motor disorders), PhenoCube (continuous behavioral observation), and eCube (pharmaco-EEG analysis). These platforms work synergistically to predict therapeutic potential of compounds through machine learning. The service portfolio includes behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, microdialysis, PK/PD analysis, and receptor occupancy studies. PsychoGenics supports multiple therapeutic areas including mental illness, neurodegenerative disorders, neurodevelopmental disorders, neuromuscular disorders, pain disorders, rare CNS disorders, and sleep/seizure disorders. Emerging therapy capabilities include cell and gene therapy, psychedelics, and microbiome research.

Product and service16 records
1SmartCube®
CategoryCore AI Platform
Description

Automated high-throughput behavioral phenotyping platform that uses machine learning classifiers to extract behavioral signatures from millions of data points per mouse per session and predict therapeutic potential of novel compounds by comparison with a proprietary reference database of marketed drugs. Used for neuropsychiatric disorder drug discovery.

2NeuroCube®
CategoryCore AI Platform
Description

AI-driven gait analysis platform using computer vision to detect changes in gait geometry and dynamics in rodent models for assessing motor impairment disorders and pain treatments.

3PhenoCube®
CategoryCore AI Platform
Description

Continuous day-and-night observation platform that tracks social, circadian, motor, and cognitive behaviors in mice over extended periods using complex computer vision and automation to detect subtle disease phenotype changes.

4eCube®
CategoryCore AI Platform
Description

Pharmaco-EEG platform that records actigraphy and quantitative EEG from unanesthetized mice before and after drug administration, using proprietary machine learning classifiers and reference database to predict therapeutic utility at drug class and subclass levels.

5Behavioral and In Vivo Testing
CategoryPreclinical CNS Service
Description

Comprehensive behavioral testing services offering over 50 behavioral assays applicable to most CNS disorders, with over 30 validated rodent disease models and surgical expertise for CNS dosing and implant placement.

6Drug Abuse Liability Services
CategoryPreclinical CNS Service
Description

Specialized preclinical testing for drug abuse potential including self-administration, drug discrimination, conditioned place preference, relapse, and withdrawal models using rodent models.

7EEG Studies
CategoryPreclinical CNS Service
Description

Full suite of preclinical EEG services including auditory evoked potentials, sleep/wake analyses, pharmaco-EEG, seizure analyses, longitudinal studies, power analysis, local field potential, and telemetry (tethered, wireless, piezoelectric), capable of recording up to 64 rats or mice simultaneously.

8Electrophysiology
CategoryPreclinical CNS Service
Description

Preclinical electrophysiology services including slice electrophysiology, in vivo electrophysiology, long-term potentiation (LTP), long-term depression (LTD), whole-cell patch clamp, and neuronal network stimulation, recording, and analysis.

9Ex Vivo Sample Biomarker Analysis
CategoryPreclinical CNS Service
Description

Biomarker analysis services including cell culture assays, transcript analysis by qPCR and RNAscope in situ hybridization, protein quantification by Western blot, and single/multiplex immunoassays using MesoScale, Luminex, Quanterix, and LC-MS/MS platforms.

10Histology and Immunohistochemistry (IHC)
CategoryPreclinical CNS Service
Description

High-throughput quantitative histology services with expertise in sectioning and staining all rodent tissue types, specialized in CNS tissues, with advanced multiple immunohistochemical labeling procedures.

11Microdialysis
CategoryPreclinical CNS Service
Description

Single or dual probe microdialysis studies for measuring neurotransmitters, peptides, and proteins in brain, blood, and other tissues, including push-pull microdialysis for large molecules and retrodialysis for drug delivery.

12Pharmacokinetic and Pharmacodynamic (PK/PD) Services
CategoryPreclinical CNS Service
Description

Comprehensive preclinical PK and biomarker assessment combining in vivo dosing and tissue sampling with analytical platforms including LC-MS/MS for small molecules and peptides, and ELISA-based assays for larger molecules.

13Receptor Occupancy Services
CategoryPreclinical CNS Service
Description

In vivo and ex vivo receptor occupancy services using selective radioligands and receptor autoradiography with the BeaQuant digital real-time autoradiography system, including in vivo receptor occupancy using LC-MS/MS for cold RO studies.

14Cell and Gene Therapy Development
CategoryEmerging Therapy Service
Description

Preclinical testing services for cell and gene therapy products including AAV viral vectors, oligonucleotides, small molecules, and adoptive cell therapies, with BSL2 facilities and CNS dosing capabilities.

15Psychedelics Research
CategoryEmerging Therapy Service
Description

Preclinical psychedelic research services with DEA schedule 1 drug handling capabilities, including secure storage infrastructure and custody protocols for studies with psilocybin, MDMA analogs, and CBD compounds.

16Microbiome Research
CategoryEmerging Therapy Service
Description

Preclinical microbiome research services exploring interactions between microbiome, drug products, and health outcomes with controlled environment for consistency and minimized variability.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

Awarded a $1 million SBIR grant to use AI tools for drug discovery targeting mental health disorders. The project aims to develop new treatments for complex neuropsychiatric disorders through machine learning and novel chemistry exploration.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-11
Description

Ongoing drug discovery collaboration extended in October 2022. PsychoGenics applies its Cube platforms and preclinical capabilities to discover novel CNS therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Shared-risk partnership for drug discovery using PsychoGenics' Cube platforms. Sunovion has collaborated with PsychoGenics to discover novel compounds for neuropsychiatric disorders.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Shared-risk partnership using PsychoGenics' AI-enabled drug discovery platforms for CNS therapeutic programs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration using SmartCube platform to discover ulotaront (SPD-503), an antipsychotic devoid of dopamine D2 receptor activity. Compound progressed to Phase III clinical trials for schizophrenia, depression, and anxiety.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-term collaboration and member of the TSC Preclinical Consortium. PsychoGenics characterizes mouse models of tuberous sclerosis complex and provides robust protocols for preclinical screening of novel therapies. Collaboration highlighted on Rare Disease Day.

7SMA Foundation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for spinal muscular atrophy drug discovery research. PsychoGenics provides preclinical testing services and disease model expertise.

psychogenics.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

20+ year collaboration on Huntington's disease research. PsychoGenics has worked closely with CHDI characterizing mouse models of Huntington's disease, resulting in numerous publications and validated disease models.

9CMTA
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Charcot-Marie-Tooth Association partnership for preclinical research in neuromuscular disorders. PsychoGenics supports CMT disease model characterization and drug discovery.

psychogenics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for Parkinson's disease drug discovery research, utilizing PsychoGenics' disease models and preclinical capabilities.

11Christopher & Dana Reeve Foundation
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for spinal cord injury research. PsychoGenics supports preclinical studies for neuroprotection and functional recovery therapeutics.

psychogenics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for rare disease drug discovery research using PsychoGenics' preclinical platforms.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CRO/CDMO with broad preclinical capabilities including CNS and behavioral testing. Comparable in preclinical service delivery to biopharma clients, though vastly larger and more diversified across geographies and modalities.

TypeBroad incumbent
Description

One of the largest preclinical CROs globally with significant CNS and behavioral services. Comparable as a direct competitor in preclinical safety, behavioral, and CNS efficacy studies, though Charles River is far broader and more diversified across therapeutic areas.

TypeBroad incumbent
Description

Large clinical and preclinical CRO offering CNS, safety assessment, and biomarker services. Comparable in offering preclinical CNS studies alongside a much broader clinical and diagnostic portfolio.

TypeEmerging player
Description

AI-driven drug discovery company using phenotypic high-content imaging and machine learning. Comparable as a tech-forward phenotypic drug discovery platform, though Recursion is asset-driven rather than a fee-for-service CRO.

TypeDirect peer
Description

U.S.-based preclinical CRO providing GLP and research-grade services to biologics developers. Comparable as a mid-sized preclinical CRO targeting biopharma sponsors, with growing CNS-adjacent capabilities.

TypeDirect peer
Description

European-headquartered CRO/CDMO with deep CNS and neuroscience discovery capabilities, including AI-enabled drug discovery and shared-risk partnerships with pharma. Highly comparable as a discovery-focused CRO with strong CNS emphasis and tech-forward platforms.

TypeDirect peer
Description

French preclinical CRO specialized in behavioral pharmacology and CNS efficacy models. Highly comparable as a smaller, specialist CNS preclinical CRO competing for similar biopharma and academic clients.

TypeDirect peer
Description

Preclinical CRO with translational platforms for oncology and other therapeutic areas, including CNS-related efficacy and biomarker work. Comparable in the preclinical CRO business model and pharma/biotech client base.

TypeDirect peer
Description

U.S.-based preclinical CRO providing safety assessment, neurobehavioral, and research models. Directly comparable in preclinical CNS services, particularly behavioral and surgical models used in CNS drug discovery.

TypeBroad incumbent
Description

Global testing services group with preclinical and central laboratory capabilities relevant to CNS research. Comparable as a contract research services provider to biopharma clients in pharma discovery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers13 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PsychoGenics

Preclinical Contract Research Servicespsychogenics.com

PsychoGenics is a private CNS-focused preclinical CRO that combines AI-enabled phenotypic drug discovery platforms (SmartCube, NeuroCube, PhenoCube, eCube) with full-service preclinical testing for biopharma, disease foundations, government agencies, and academic institutions.

What PsychoGenics does

PsychoGenics is a private, CNS-focused preclinical contract research organization (CRO) headquartered in Paramus, New Jersey, founded in 1999. The company combines a comprehensive suite of standard preclinical services (behavioral testing, electrophysiology, EEG, biomarker analysis, histology, microdialysis, PK/PD, receptor occupancy) with four proprietary AI-enabled phenotypic drug discovery platforms branded as the Cube technologies: SmartCube (high-throughput automated behavioral phenotyping with ML classifiers trained on thousands of reference compounds), NeuroCube (computer vision-based gait analysis for motor and pain disorders), PhenoCube (continuous day-and-night observation of social, circadian, motor, and cognitive behaviors), and eCube (pharmaco-EEG with proprietary qEEG reference database). The SmartCube platform notably contributed to the discovery of ulotaront, now in Phase III clinical trials with Sumitomo Pharma for schizophrenia, depression, and anxiety. The company maintains AAALAC International accreditation (since 2007), PHS OLAW Assurance (since 2005), and DEA Schedule 1 handling capability, and has established more than 400 client relationships with a >70% client return rate.

PsychoGenics generates revenue through three primary streams: (1) fee-for-service preclinical CRO contracts for biopharmaceutical companies, academic institutions, and disease research foundations; (2) shared-risk drug discovery partnerships with major pharma (Sunovion, Roche, Karuna Therapeutics, Sumitomo Pharma), where the company applies its Cube platforms to discover novel compounds potentially yielding licensing/milestone revenue; and (3) non-dilutive government research grants and contracts, including a recent $80M NIH HEAL Initiative IDIQ contract over five years for pain therapeutic screening and SBIR grants from NIMH for rare disease and mental health programs. The company serves named customers including Sumitomo Pharma, Sunovion, Roche, Karuna Therapeutics, NIH/NIMH, the SMA Foundation, CHDI Foundation, TSC Alliance, CMTA, Michael J. Fox Foundation, Christopher & Dana Reeve Foundation, and Grace Science. Recent product line extensions include cell and gene therapy preclinical testing, psychedelics research, and microbiome studies, expanding beyond traditional CNS behavioral services.

The go-to-market motion is sales-led and B2B, relying on direct enterprise field sales, conference engagement (Society for Neuroscience, NNT, AHS), the Scientist.com marketplace (where the company achieved top supplier status), and long-term disease foundation partnerships that serve as both collaborators and referral channels. Pricing is quote-based and project-specific rather than publicly disclosed. The company has 101-250 employees, over 20% holding Ph.D.s, and is led by President and CEO Emer Leahy, Ph.D., MBA, with a Ph.D.-credentialed executive team across innovation, operations, research, and commercial functions.

PsychoGenics firmographics

Firmographics
Name
PsychoGenics
Legal name
PsychoGenics Inc.
Website
https://psychogenics.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
PsychoGenics is a private CNS-focused preclinical CRO that combines AI-enabled phenotypic drug discovery platforms (SmartCube, NeuroCube, PhenoCube, eCube) with full-service preclinical testing for biopharma, disease foundations, government agencies, and academic institutions.
Ownership category
akta.pro rank

PsychoGenics industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Preclinical CNS research
  • Contract research organization
  • Phenotypic drug discovery
  • Behavioral pharmacology services
  • AI-enabled in vivo platforms

Where PsychoGenics is headquartered

Location

Headquarters

HQ city
Paramus
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PsychoGenics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Preclinical CRO Contract Services: PsychoGenics generates revenue primarily through fee-for-service contracts for preclinical CNS drug discovery research. Services include behavioral testing, electrophysiology, EEG studies, biomarker analysis, histology, microdialysis, PK/PD, and receptor occupancy studies. Revenue is project-based and recurring as clients return for additional studies (>70% client return rate).
  2. Shared-Risk Drug Discovery Partnerships: PsychoGenics enters shared-risk partnerships with biopharma companies (Sunovion, Roche, Karuna) where the company applies its Cube platforms to discover novel compounds. Partnerships may include licensing of discovered compounds or milestone payments, representing an additional revenue stream alongside service fees.
  3. Government Research Grants: PsychoGenics receives SBIR grants from NIH (NIMH) and government contracts (NIH HEAL Initiative) to fund specific drug discovery programs. These grants (e.g., $3M SBIR, $80M NIH IDIQ contract) provide non-dilutive funding for research activities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom preclinical study contracts — pricing negotiated per project based on scope of work, animal model, and assay requirements.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

PsychoGenics product offering

Product offering

Core offering

PsychoGenics is a preclinical contract research organization (CRO) that provides CNS-focused drug discovery and research services to biopharmaceutical companies, disease foundations, and government agencies. The company combines proprietary AI-enabled phenotypic platforms (SmartCube, NeuroCube, PhenoCube, eCube) with a full suite of preclinical services including behavioral testing, electrophysiology, EEG, biomarker analysis, histology, microdialysis, PK/PD, and receptor occupancy studies. It also engages in shared-risk drug discovery partnerships with major pharma, leading to clinical-stage compounds such as ulotaront.

Product overview

PsychoGenics is a preclinical Contract Research Organization (CRO) specializing in CNS and orphan disorder drug discovery. The company offers a platform-plus-services architecture centered on four proprietary AI-enabled Cube platforms: SmartCube (high-throughput behavioral phenotyping), NeuroCube (gait analysis for motor disorders), PhenoCube (continuous behavioral observation), and eCube (pharmaco-EEG analysis). These platforms work synergistically to predict therapeutic potential of compounds through machine learning. The service portfolio includes behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, microdialysis, PK/PD analysis, and receptor occupancy studies. PsychoGenics supports multiple therapeutic areas including mental illness, neurodegenerative disorders, neurodevelopmental disorders, neuromuscular disorders, pain disorders, rare CNS disorders, and sleep/seizure disorders. Emerging therapy capabilities include cell and gene therapy, psychedelics, and microbiome research.

Differentiator

Problem solved

Functional benefit

Products and services

  • SmartCube® Automated high-throughput behavioral phenotyping platform that uses machine learning classifiers to extract behavioral signatures from millions of data points per mouse per session and predict therapeutic potential of novel compounds by comparison with a proprietary reference database of marketed drugs. Used for neuropsychiatric disorder drug discovery.
  • NeuroCube® AI-driven gait analysis platform using computer vision to detect changes in gait geometry and dynamics in rodent models for assessing motor impairment disorders and pain treatments.
  • PhenoCube® Continuous day-and-night observation platform that tracks social, circadian, motor, and cognitive behaviors in mice over extended periods using complex computer vision and automation to detect subtle disease phenotype changes.
  • eCube® Pharmaco-EEG platform that records actigraphy and quantitative EEG from unanesthetized mice before and after drug administration, using proprietary machine learning classifiers and reference database to predict therapeutic utility at drug class and subclass levels.
  • Behavioral and In Vivo Testing Comprehensive behavioral testing services offering over 50 behavioral assays applicable to most CNS disorders, with over 30 validated rodent disease models and surgical expertise for CNS dosing and implant placement.
  • Drug Abuse Liability Services Specialized preclinical testing for drug abuse potential including self-administration, drug discrimination, conditioned place preference, relapse, and withdrawal models using rodent models.
  • EEG Studies Full suite of preclinical EEG services including auditory evoked potentials, sleep/wake analyses, pharmaco-EEG, seizure analyses, longitudinal studies, power analysis, local field potential, and telemetry (tethered, wireless, piezoelectric), capable of recording up to 64 rats or mice simultaneously.
  • Electrophysiology Preclinical electrophysiology services including slice electrophysiology, in vivo electrophysiology, long-term potentiation (LTP), long-term depression (LTD), whole-cell patch clamp, and neuronal network stimulation, recording, and analysis.
  • Ex Vivo Sample Biomarker Analysis Biomarker analysis services including cell culture assays, transcript analysis by qPCR and RNAscope in situ hybridization, protein quantification by Western blot, and single/multiplex immunoassays using MesoScale, Luminex, Quanterix, and LC-MS/MS platforms.
  • Histology and Immunohistochemistry (IHC) High-throughput quantitative histology services with expertise in sectioning and staining all rodent tissue types, specialized in CNS tissues, with advanced multiple immunohistochemical labeling procedures.
  • Microdialysis Single or dual probe microdialysis studies for measuring neurotransmitters, peptides, and proteins in brain, blood, and other tissues, including push-pull microdialysis for large molecules and retrodialysis for drug delivery.
  • Pharmacokinetic and Pharmacodynamic (PK/PD) Services Comprehensive preclinical PK and biomarker assessment combining in vivo dosing and tissue sampling with analytical platforms including LC-MS/MS for small molecules and peptides, and ELISA-based assays for larger molecules.
  • Receptor Occupancy Services In vivo and ex vivo receptor occupancy services using selective radioligands and receptor autoradiography with the BeaQuant digital real-time autoradiography system, including in vivo receptor occupancy using LC-MS/MS for cold RO studies.
  • Cell and Gene Therapy Development Preclinical testing services for cell and gene therapy products including AAV viral vectors, oligonucleotides, small molecules, and adoptive cell therapies, with BSL2 facilities and CNS dosing capabilities.
  • Psychedelics Research Preclinical psychedelic research services with DEA schedule 1 drug handling capabilities, including secure storage infrastructure and custody protocols for studies with psilocybin, MDMA analogs, and CBD compounds.
  • Microbiome Research Preclinical microbiome research services exploring interactions between microbiome, drug products, and health outcomes with controlled environment for consistency and minimized variability.

Quantifiable outcome

  • A potential clinical candidate can be identified after screening fewer than 300 compounds in lead optimization — a fraction of compounds typically tested in target-based approaches — substantially reducing discovery timelines and costs.
  • +3 more outcomes

Companies that use PsychoGenics

Customer profile

Named customers13 records

Segments4 records

Ideal customer profiles4 records

PsychoGenics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

PsychoGenics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and minor.

  • Collaborations PharmaceuticalscoreStrategic or Co-development Partner · 5 September 2023Awarded a $1 million SBIR grant to use AI tools for drug discovery targeting mental health disorders. The project aims to develop new treatments for complex neuropsychiatric disorders through machine learning and novel chemistry exploration.
  • Karuna TherapeuticscoreStrategic or Co-development Partner · 11 October 2022Ongoing drug discovery collaboration extended in October 2022. PsychoGenics applies its Cube platforms and preclinical capabilities to discover novel CNS therapeutics.
  • SunovioncoreStrategic or Co-development PartnerShared-risk partnership for drug discovery using PsychoGenics' Cube platforms. Sunovion has collaborated with PsychoGenics to discover novel compounds for neuropsychiatric disorders.
  • RochecoreStrategic or Co-development PartnerShared-risk partnership using PsychoGenics' AI-enabled drug discovery platforms for CNS therapeutic programs.
  • Sumitomo PharmacoreStrategic or Co-development PartnerCollaboration using SmartCube platform to discover ulotaront (SPD-503), an antipsychotic devoid of dopamine D2 receptor activity. Compound progressed to Phase III clinical trials for schizophrenia, depression, and anxiety.
  • TSC AlliancecoreStrategic or Co-development PartnerLong-term collaboration and member of the TSC Preclinical Consortium. PsychoGenics characterizes mouse models of tuberous sclerosis complex and provides robust protocols for preclinical screening of novel therapies. Collaboration highlighted on Rare Disease Day.
  • SMA FoundationcoreStrategic or Co-development PartnerPartnership for spinal muscular atrophy drug discovery research. PsychoGenics provides preclinical testing services and disease model expertise.
  • CHDI FoundationcoreStrategic or Co-development Partner20+ year collaboration on Huntington's disease research. PsychoGenics has worked closely with CHDI characterizing mouse models of Huntington's disease, resulting in numerous publications and validated disease models.
  • CMTAminorStrategic or Co-development PartnerCharcot-Marie-Tooth Association partnership for preclinical research in neuromuscular disorders. PsychoGenics supports CMT disease model characterization and drug discovery.
  • Michael J. Fox FoundationminorStrategic or Co-development PartnerPartnership for Parkinson's disease drug discovery research, utilizing PsychoGenics' disease models and preclinical capabilities.
  • Christopher & Dana Reeve FoundationminorStrategic or Co-development PartnerPartnership for spinal cord injury research. PsychoGenics supports preclinical studies for neuroprotection and functional recovery therapeutics.
  • Grace ScienceminorStrategic or Co-development PartnerPartnership for rare disease drug discovery research using PsychoGenics' preclinical platforms.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

PsychoGenics competitors and assessment

Company assessment

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO with broad preclinical capabilities including CNS and behavioral testing. Comparable in preclinical service delivery to biopharma clients, though vastly larger and more diversified across geographies and modalities.
  • Charles River Laboratories: One of the largest preclinical CROs globally with significant CNS and behavioral services. Comparable as a direct competitor in preclinical safety, behavioral, and CNS efficacy studies, though Charles River is far broader and more diversified across therapeutic areas.
  • Labcorp Drug Development (Covance): Large clinical and preclinical CRO offering CNS, safety assessment, and biomarker services. Comparable in offering preclinical CNS studies alongside a much broader clinical and diagnostic portfolio.
  • Eurofins Scientific: Global testing services group with preclinical and central laboratory capabilities relevant to CNS research. Comparable as a contract research services provider to biopharma clients in pharma discovery.

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery company using phenotypic high-content imaging and machine learning. Comparable as a tech-forward phenotypic drug discovery platform, though Recursion is asset-driven rather than a fee-for-service CRO.

Direct peers

  • Bionova Scientific: U.S.-based preclinical CRO providing GLP and research-grade services to biologics developers. Comparable as a mid-sized preclinical CRO targeting biopharma sponsors, with growing CNS-adjacent capabilities.
  • Evotec SE: European-headquartered CRO/CDMO with deep CNS and neuroscience discovery capabilities, including AI-enabled drug discovery and shared-risk partnerships with pharma. Highly comparable as a discovery-focused CRO with strong CNS emphasis and tech-forward platforms.
  • Porsolt: French preclinical CRO specialized in behavioral pharmacology and CNS efficacy models. Highly comparable as a smaller, specialist CNS preclinical CRO competing for similar biopharma and academic clients.
  • Crown Bioscience: Preclinical CRO with translational platforms for oncology and other therapeutic areas, including CNS-related efficacy and biomarker work. Comparable in the preclinical CRO business model and pharma/biotech client base.
  • Inotiv: U.S.-based preclinical CRO providing safety assessment, neurobehavioral, and research models. Directly comparable in preclinical CNS services, particularly behavioral and surgical models used in CNS drug discovery.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

PsychoGenics social profiles

Digital presence

PsychoGenics compliance and trust

Trust signal

Compliance3 records

PsychoGenics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PsychoGenics leadership team

Management profile

Number of profiles

Profiles8 records

PsychoGenics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PsychoGenics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PsychoGenics

What does PsychoGenics do?

PsychoGenics is a preclinical contract research organization (CRO) that provides CNS-focused drug discovery and research services to biopharmaceutical companies, disease foundations, and government agencies. The company combines proprietary AI-enabled phenotypic platforms (SmartCube, NeuroCube, PhenoCube, eCube) with a full suite of preclinical services including behavioral testing, electrophysiology, EEG, biomarker analysis, histology, microdialysis, PK/PD, and receptor occupancy studies. It also engages in shared-risk drug discovery partnerships with major pharma, leading to clinical-stage compounds such as ulotaront.

Is PsychoGenics a public or private company?

PsychoGenics is a private company. It is classified as management employee owned and is currently operating.

When was PsychoGenics founded?

PsychoGenics was founded in 2002. It employs 101 to 250 people.

Where is PsychoGenics based?

PsychoGenics is headquartered in Paramus, United States, in the North America region.

How does PsychoGenics make money?

Three revenue lines are on record. Preclinical CRO Contract Services are the primary driver. The others are shared-Risk Drug Discovery Partnerships and government Research Grants.

Who are PsychoGenics's main competitors?

Broad incumbents on record are WuXi AppTec, Charles River Laboratories, Labcorp Drug Development (Covance) and Eurofins Scientific. Recursion Pharmaceuticals is listed as an emerging player. Direct peers are Bionova Scientific, Evotec SE, Porsolt, Crown Bioscience and Inotiv.

Does PsychoGenics have an API?

No public API is recorded for PsychoGenics.

What industry is PsychoGenics in?

PsychoGenics's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comIn Vivo CRO Market Growth in Future Scope 2025-2032 | IQVIA Inc., Crown Bioscience, Taconic Biosciences, Inc., PsychoGenics IncThe global in vivo CRO market is projected to grow from USD 5.11 billion in 2025 to USD 9.17 billion by 2032, a CAGR of 8.7%. The report covers segmentation by molecule type, therapeutic area, service type, and region, and lists major players including IQVIA, Crown Bioscience, and Taconic Biosciences.YahooPsychoGenics Inc. Awarded $3 Million SBIR Grant to Employ Its AI-Enabled Platforms to Find Treatments for Rare DisordersPsychoGenics received a $3 million SBIR grant from NIMH to use its eCube AI platform to repurpose existing drugs for rare diseases. The grant covers four years and targets about 10,000 rare diseases affecting up to 400 million people, with 90% lacking treatments. Success could expand to more rare disorders.Business Wire BlogPsychoGenics Inc. Awarded $3 Million SBIR Grant to Employ Its AI-Enabled Platforms to Find Treatments for Rare DisordersPsychoGenics received a $3 million SBIR grant from NIMH to use its eCube AI-enabled EEG platform for repurposing existing drugs for rare diseases. The grant will evaluate rare disease mouse models to predict treatments, aiming to address 10,000 rare diseases affecting up to 400 million people.FinSMEsPsychoGenics Receives $3M SBIR GrantPsychoGenics received a $3 million SBIR grant from the NIMH to develop its eCube® AI-enabled EEG platform for identifying novel applications of existing drugs targeting rare diseases. The company utilizes this funding to advance machine learning tools and expand its drug discovery capabilities, which have previously partnered with pharmaceutical firms like Sunovion, Roche, and Karuna.PsychogenicsPsychoGenics Inc. Awarded $3 million SBIR Grant to Employ its AI-enabled Platforms to Find Treatments for Rare DisordersPsychoGenics Inc. has been awarded a Fast Track Small Business Innovation Research grant worth up to $3 million by the National Institute of Mental Health to support drug discovery for rare disorders. The funding will enable PsychoGenics to utilize its proprietary eCube® AI-enabled EEG platform and machine learning tools to identify novel applications for existing drugs targeting these conditions. This initiative aims to rapidly bring treatment options to patients with limited or no current therapies by repurposing known compounds.YahooTHE CHRISTOPHER & DANA REEVE FOUNDATION ANNOUNCES $3.1M SPINAL CORD INJURY RESEARCH GRANTSThe Christopher & Dana Reeve Foundation announced $3.1 million in grants to .NeuroRestore and PsychoGenics for spinal cord injury research. The funds support clinical trials for bladder dysfunction and a brain-spine interface to reverse upper limb paralysis, plus a preclinical study for standardized testing.PsychogenicsReeve Foundation Announces $3.1M Spinal Cord Injury Research GrantsThe Christopher & Dana Reeve Foundation announced $3.1 million in research grants to .NeuroRestore and PsychoGenics to fund spinal cord injury clinical trials and preclinical studies. The funding supports the development of brain-spine interface technology by ONWARD Medical for limb function restoration, epidural stimulation for bladder dysfunction, and standardized testing models.PR NewswireTHE CHRISTOPHER & DANA REEVE FOUNDATION ANNOUNCES $3.1M SPINAL CORD INJURY RESEARCH GRANTSThe Christopher & Dana Reeve Foundation announced $3.1 million in new research grants to support clinical trials and scientific tools for spinal cord injury treatments. The funding is distributed among .NeuroRestore, which will receive two grants totaling $2.6 million for brain-spine interface and bladder dysfunction studies, and PsychoGenics, which received a $522,000 grant for standardized preclinical testing models.ZapierBeyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenicsThe Beyond Biotech podcast episode covers World Antimicrobial Awareness Week with interviews on antimicrobial resistance and a collaboration between Emyria and PsychoGenics. Emyria will screen five novel MDMA analogs using PsychoGenics' AI platform SmartCube to accelerate preclinical development for neuropsychiatric disorders.BioSpacePsychoGenics’ High Data Security Standards Are Certified by The NIHThe NIH completed an assessment of PsychoGenics' data/IT security standards and granted official authority to operate as a government contractor. PsychoGenics, which screens pain research candidates under NINDS, will continue to pressure-test its systems. The company holds a 5-year contract worth up to $49.9 million.